Table 1.
Ongoing clinical trials in endometrial cancer
| Trial identifier | Disease characteristics in patient population | Treatment arms | Trial No |
| Primary adjuvant treatment | |||
| GY020 | Stage I/II dMMR endometrioid tumours | Local radiation Local radiation and pembrolizumab |
NCT04214067 |
| RUBY | Advanced or recurrent disease | Carboplatin and paclitaxel, and dostarlimab → dostarlimab every 6 weeks up to 3 years Carboplatin and paclitaxel, and placebo → placebo |
NCT03981796 |
| GY018 | Advanced or recurrent disease | Carboplatin and paclitaxel, and pembrolizumab → pembrolizumab every 3 weeks up to 5 years Carboplatin and paclitaxel, and placebo → placebo |
NCT03914612 |
| AtTEnd | Advanced or recurrent disease | Carboplatin and paclitaxel, and atezolizumab → atezolizumab every 3 weeks to disease progression Carboplatin and paclitaxel, and placebo → placebo |
NCT03603184 |
| GOG3053/KEYNOTE-B21/ENGOT-en11 | Non-endometrioid stage I/II with myometrial invasion TP53 aberrant tumours Stage III/IV |
Carboplatin and paclitaxel, and pembrolizumab → pembrolizumab, six cycles Carboplatin and paclitaxel, and placebo → placebo |
NCT04634877 |
| LEAP001 | Advanced or recurrent disease | Carboplatin and paclitaxel Lenvatinib and pembrolizumab |
NCT03884101 |
| GOG3064 | Advanced or recurrent disease with dMMR tumours | Carboplatin and paclitaxel Pembrolizumab |
NCT05173987 |
| Maintenance treatment | |||
| DUO-E | Advanced or recurrent disease | Carboplatin and paclitaxel, and placebo → placebo Carboplatin and paclitaxel, and durvalumab → durvalumab every 4 weeks and placebo Carboplatin and paclitaxel, and durvalumab → durvaulmab every 4 weeks and olaparib |
NCT04269200 |
| PARPI maintenance | Advanced or recurrent disease | Rucaparib until disease progression Placebo |
NCT03617679 |
| SIENDO | Stage IV or first relapse | Selinexor until disease progression Placebo |
NCT03555422 |
| Recurrent disease | |||
| GY012 | Recurrent | Cediranib Olaparib Olaparib and cediranib Olaparib and capivasertib Olaparib and durvalumab Cediranib and durvalumab |
NCT03660826 |
| GOG3038/PODIUM/ENGOT-en12 | Advanced or recurrent disease | No previous treatment involving checkpoint inhibitors MSI-H: retifanliimab; dMMR or POLE: retifanlimab Previous treatment involving checkpoint inhibitors Unselected: retifanlimab and epacadostat Fibroblast growth factor receptor 1/2/3 mutation: retifanlimab and pemgatinib |
NCT04463771 |
| ADAGIO | Recurrent or persistent uterine serous carcinomas | Adavosertib | NCT04590248 |
| GOG3039 | Advanced or recurrent | Abemaciclib and letrazole | NCT04393285 |
| Solely molecularly driven treatments | |||
| PORTEC-4a | Stage I/II, high intermediate risk | Favourable disease: observation Intermediate: vaginal brachytherapy Unfavourable: external beam radiation |
NCT03469674 |
| TAPER | Stage I/II, high intermediate risk, POLE and p53 wild type | No treatment | NCT04705649 |
| RAINBO | Stage I-IV | TP53 Chemotherapy Chemotherapy and olaparib dMMR Radiation Radiation and durvalumab No specific molecular profile Chemoradiation Radiation and megestrol acetate POLE mutation Observation |
NCT05255653 |
Table does not include all ongoing trials, because more than 900 clinical trials for endometrial cancer were listed on ClinicalTrials.gov at time of publication. Arrows indicate the second stage of the trial. dMMR=mismatch repair deficient tumours; MSI-H=microsatellite instability, hypermutated; POLE=DNA polymerase ε; TP53=tumour protein p53; PARPI=poly-ADP ribose polymerase inhibitors.